CompletedPhase 1NCT01555268

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Studying Acute erythroid leukemia

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Roswell Park Cancer Institute
Principal Investigator: Eunice Wang, RPH
Roswell Park Cancer Institute
Intervention: trebananib(biological)
Enrollment: 24 enrolled
Eligibility: 18 years · All sexes
Timeline: 2011 – 2016

Study locations (2)

Roswell Park Cancer Institute, Buffalo, New York, United States
University of Rochester, Rochester, New York, United States

Collaborators

Amgen

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01555268 on ClinicalTrials.gov

Other trials for Acute erythroid leukemia

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT00658814
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)

See all trials for Acute erythroid leukemia →

← Back to all trials